Abstract: One of the relatively newer classes of medication used to treat diabetes are the dipeptidyl peptidase-IV inhibitors, which are increasing in use due to their efficacy, tol-erability, and the option to use them in renally impaired patients. Here, we report a patient, a practicing physician, who developed severe arthralgias on the DPP-IV inhibitors sitagliptin and saxagliptin.
Publication Year: 2012
Publication Date: 2012-11-27
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
Cited By Count: 5
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot